Joseph Patti
Direttore/Membro del Consiglio presso ARMATA PHARMACEUTICALS, INC.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di Joseph Patti
Società | Posizione | Inizio | Fine |
---|---|---|---|
ARMATA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 09/05/2019 | - |
Independent Dir/Board Member | 09/05/2019 | - | |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | Direttore/Membro del Consiglio | 01/03/2019 | - |
JP Biotech Advisors, Inc. | Presidente | 01/02/2018 | - |
Storia della carriera di Joseph Patti
Precedenti posizioni note di Joseph Patti
Società | Posizione | Inizio | Fine |
---|---|---|---|
Evecxia, Inc.
Evecxia, Inc. Miscellaneous Commercial ServicesCommercial Services Evecxia, Inc. is engaged in biotechnology services. The company was founded by Jacob Jacobsen and Marc Caron and is headquartered in Research Triangle Park, NC. | Direttore/Membro del Consiglio | 01/06/2022 | 14/09/2023 |
Amministratore Delegato | 01/06/2022 | 14/09/2023 | |
Presidente | 01/06/2022 | 14/09/2023 | |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Direttore/Membro del Consiglio | 01/08/2019 | 01/07/2021 |
Amministratore Delegato | 01/08/2019 | 01/07/2021 | |
Presidente | 01/11/2018 | 01/08/2019 | |
Presidente | 01/08/2019 | 01/07/2021 | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Direttore/Membro del Consiglio | 01/10/2014 | 01/02/2018 |
Amministratore Delegato | 01/10/2014 | 01/02/2018 | |
Corporate Officer/Principal | 12/11/2012 | 01/10/2014 | |
Presidente | 01/10/2014 | 01/02/2018 | |
SciStem, Inc.
SciStem, Inc. Pharmaceuticals: MajorHealth Technology SciStem, Inc. operated as an early stage regenerative medicine company developed novel cell and cell-based gene therapies for bone healing and musculoskeletal indications in people and pets. The company was headquartered in Athens, GA. | Direttore/Membro del Consiglio | 01/01/2012 | 01/01/2015 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Direttore/Membro del Consiglio | 01/01/1998 | 01/01/2005 |
Direttore Tecnico/Scientifico/R&S | 01/05/1994 | 01/02/2012 | |
Fondatore | 01/05/1994 | 01/02/2012 | |
Institute of Biosciences & Technology | Corporate Officer/Principal | 01/01/1994 | 01/01/1998 |
░░░░░ ░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
░░░░░░░░░ | - | - |
Formazione di Joseph Patti
University of Pittsburgh | Undergraduate Degree |
The University of Alabama at Birmingham | Doctorate Degree |
The University of Miami Leonard M. Miller School of Medicine | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 15 |
Posizioni
Director/Board Member | 7 |
President | 5 |
Chief Executive Officer | 4 |
Settori
Health Technology | 7 |
Consumer Services | 6 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
VAXART, INC. | Health Technology |
ARMATA PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 7 |
---|---|
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | Health Technology |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
SciStem, Inc.
SciStem, Inc. Pharmaceuticals: MajorHealth Technology SciStem, Inc. operated as an early stage regenerative medicine company developed novel cell and cell-based gene therapies for bone healing and musculoskeletal indications in people and pets. The company was headquartered in Athens, GA. | Health Technology |
Evecxia, Inc.
Evecxia, Inc. Miscellaneous Commercial ServicesCommercial Services Evecxia, Inc. is engaged in biotechnology services. The company was founded by Jacob Jacobsen and Marc Caron and is headquartered in Research Triangle Park, NC. | Commercial Services |
JP Biotech Advisors, Inc. | |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | Technology Services |
- Borsa valori
- Insiders
- Joseph Patti
- Esperienza